228 related articles for article (PubMed ID: 19585395)
1. The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets.
Berwaerts J; Cleton A; Herben V; van de Vliet I; Chang I; van Hoek P; Eerdekens M
Pharmacopsychiatry; 2009 Jul; 42(4):158-63. PubMed ID: 19585395
[TBL] [Abstract][Full Text] [Related]
2. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
Fowler JA; Bettinger TL; Argo TR
Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
[TBL] [Abstract][Full Text] [Related]
3. No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects.
Thyssen A; Cleton A; Talluri K; Leempoels J; Janssens L; Boom S; Eerdekens M
Hum Psychopharmacol; 2009 Oct; 24(7):532-9. PubMed ID: 19693799
[TBL] [Abstract][Full Text] [Related]
4. Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects.
Si T; Shu L; Liu Y; Su YA; Guo C; Zhang H
Hum Psychopharmacol; 2010 Jul; 25(5):404-9. PubMed ID: 20589922
[TBL] [Abstract][Full Text] [Related]
5. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.
Berwaerts J; Cleton A; Rossenu S; Talluri K; Remmerie B; Janssens L; Boom S; Kramer M; Eerdekens M
J Psychopharmacol; 2010 Jul; 24(7):1011-8. PubMed ID: 19825908
[TBL] [Abstract][Full Text] [Related]
6. Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release.
Boom S; Talluri K; Janssens L; Remmerie B; De Meulder M; Rossenu S; van Osselaer N; Eerdekens M; Cleton A
J Clin Pharmacol; 2009 Nov; 49(11):1318-30. PubMed ID: 19713555
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
Marder SR; Kramer M; Ford L; Eerdekens E; Lim P; Eerdekens M; Lowy A
Biol Psychiatry; 2007 Dec; 62(12):1363-70. PubMed ID: 17601495
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
Tzimos A; Samokhvalov V; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460
[TBL] [Abstract][Full Text] [Related]
9. Paliperidone extended-release for the treatment of schizophrenia.
Marino J; Caballero J
Pharmacotherapy; 2008 Oct; 28(10):1283-98. PubMed ID: 18823223
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia.
Luthringer R; Staner L; Noel N; Muzet M; Gassmann-Mayer C; Talluri K; Cleton A; Eerdekens M; Battisti WP; Palumbo JM
Int Clin Psychopharmacol; 2007 Sep; 22(5):299-308. PubMed ID: 17690599
[TBL] [Abstract][Full Text] [Related]
11. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.
Canuso CM; Bossie CA; Amatniek J; Turkoz I; Pandina G; Cornblatt B
Early Interv Psychiatry; 2010 Feb; 4(1):64-78. PubMed ID: 20199482
[TBL] [Abstract][Full Text] [Related]
12. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
Kramer M; Simpson G; Maciulis V; Kushner S; Vijapurkar U; Lim P; Eerdekens M
J Clin Psychopharmacol; 2007 Feb; 27(1):6-14. PubMed ID: 17224706
[TBL] [Abstract][Full Text] [Related]
13. Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials.
Janicak PG; Wu JH; Mao L
Curr Med Res Opin; 2008 Jun; 24(6):1807-15. PubMed ID: 18559166
[TBL] [Abstract][Full Text] [Related]
14. Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study.
Berwaerts J; Lane R; Nuamah IF; Lim P; Remmerie B; Hough DW
J Affect Disord; 2011 Mar; 129(1-3):252-60. PubMed ID: 20947174
[TBL] [Abstract][Full Text] [Related]
15. Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.
Pani L; Marchese G
Expert Opin Drug Deliv; 2009 Mar; 6(3):319-31. PubMed ID: 19317589
[TBL] [Abstract][Full Text] [Related]
16. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.
Gopal S; Gassmann-Mayer C; Palumbo J; Samtani MN; Shiwach R; Alphs L
Curr Med Res Opin; 2010 Feb; 26(2):377-87. PubMed ID: 20001492
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder.
Canuso CM; Lindenmayer JP; Kosik-Gonzalez C; Turkoz I; Carothers J; Bossie CA; Schooler NR
J Clin Psychiatry; 2010 May; 71(5):587-98. PubMed ID: 20492853
[TBL] [Abstract][Full Text] [Related]
18. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone.
Canuso CM; Youssef EA; Bossie CA; Turkoz I; Schreiner A; Simpson GM
Int Clin Psychopharmacol; 2008 Jul; 23(4):209-15. PubMed ID: 18545059
[TBL] [Abstract][Full Text] [Related]
19. [Treatment with paliperidone extended-release tablets in a case of resistant undifferentiated schizophrenia: clinical improvement with 12 mg and evaluation through 3TRE scale].
Rusconi AC; Carlone C; Muscillo M; Piccione M
Riv Psichiatr; 2009; 44(4):267-72. PubMed ID: 20066799
[TBL] [Abstract][Full Text] [Related]
20. Paliperidone extended release.
Yang LP; Plosker GL
CNS Drugs; 2007; 21(5):417-25; discussion 426-7. PubMed ID: 17447829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]